87 related articles for article (PubMed ID: 15194349)
1. Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine.
Silva SL; Silva SF; Cavalcante RO; Mota RS; Carvalho RA; Moraes MO; Campos HH; Moraes ME
Transplant Proc; 2004 May; 36(4):1004-6. PubMed ID: 15194349
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas.
Silva SL; Silva SF; Farias IN; Mota RS; Carvalho RA; Moraes MO; Moraes ME; Campos Hde H
Transplant Proc; 2004 May; 36(4):934-7. PubMed ID: 15194323
[TBL] [Abstract][Full Text] [Related]
3. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
4. [Proliferation effects of sirolimus, cyclosporine A and mycophenolate mofetil on human transitional cell carcinoma cells].
Lin J; Wang YH; Zhang YH; Tian Y
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):388-91. PubMed ID: 22490898
[TBL] [Abstract][Full Text] [Related]
5. Conversion from cyclosporine to mycophenolate mofetil improves expression of A20 in the rat kidney allografts undergoing chronic rejection.
Teng D; Lu Y; Gao R; Xin Y; Cao G; Li X; Wang L; Wang J; Wang L; Li Y
Transplant Proc; 2006 Sep; 38(7):2164-7. PubMed ID: 16980032
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
Yang CW; Ahn HJ; Kim WY; Li C; Kim HW; Choi BS; Cha JH; Kim YS; Kim J; Bang BK
Kidney Int; 2002 Jul; 62(1):20-30. PubMed ID: 12081560
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Yang CW; Ahn HJ; Kim WY; Li C; Jung JY; Yoon SA; Kim YS; Cha JH; Kim J; Bang BK
Transplantation; 2003 Feb; 75(3):309-15. PubMed ID: 12589150
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
9. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
10. Different effect of cyclosporine A and mycophenolate mofetil on passive Heymann nephritis in the rat.
Blume C; Heise G; Hess A; Waldner C; Grabensee B; Schroer K; Heering P
Nephron Exp Nephrol; 2005; 100(2):e104-12. PubMed ID: 15855806
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
[TBL] [Abstract][Full Text] [Related]
12. Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts.
Shimizu H; Takahashi M; Takeda S; Inoue S; Fujishiro J; Hakamata Y; Kaneko T; Murakami T; Takeyoshi I; Morishita Y; Kobayashi E
Transpl Immunol; 2004 Nov; 13(3):219-27. PubMed ID: 15381205
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
[TBL] [Abstract][Full Text] [Related]
14. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
[TBL] [Abstract][Full Text] [Related]
15. Foetal rat pancreatic transplantation: posttransplantation development of foetal pancreatic iso- and allografts and suppression of rejection with mycophenolate mofetil (MMF) and cyclosporine based immunesuppression.
du Toit D; Muller C; Page B; Louw J
Microsc Res Tech; 1998 Nov; 43(4):347-55. PubMed ID: 9849976
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
[TBL] [Abstract][Full Text] [Related]
17. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
[TBL] [Abstract][Full Text] [Related]
18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
19. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
Tojimbara T; Nakajima I; Sato S; Nakamura M; Kawase T; Kai K; Tsuda S; Kudo S; Fuchinoue S; Teraoka S
Transplant Proc; 2004 Sep; 36(7):2087-9. PubMed ID: 15518755
[TBL] [Abstract][Full Text] [Related]
20. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]